-
May 22, 2026 Cannabis and ADHDClick here to access CANNABIS AND ADHD – A CADDRA POLICY STATEMENT (2024) Thank you...
-
February 22, 2024 Foquest is now covered on the New Brunswick FormularyEffective February 20, 2024, Foquest is listed on the New Brunswick Formulary (special authorization) for the treatment...
-
January 31, 2024 ADHD Medications and Long-Term Risk of CVDCADDRA Board member Dr. Russell J. Schachar provided this commentary on a recently published JAMA...
-
December 19, 2023 Foquest is now listed on the PEI FormularyEffective December 18, 2023, Foquest is listed on the PEI Formulary (special authorization) for the treatment...
-
December 7, 2023 Foquest is now covered on the Nova Scotia FormularyEffective Dec 1, 2023, Foquest is listed on the Nova Scotia Formulary for the treatment of Attention...
-
November 3, 2023 FOQUEST now on the Alberta Drug Benefit ListEffective November 1, 2023, FOQUEST is now listed on the Alberta Drug Benefit List for the treatment...
-
November 1, 2023 Vyvanse added to innoviCares programVyvanse has been added to the innoviCares program. As part of the program,patients automatically get 5% off...
-
November 1, 2023 New ADHD meds on Alberta Drug Benefit ListOn October 1, 2023, the following ADHD medications were added to the Alberta Drug Benefit List (ADBL)...
-
September 13, 2023 New Nova Scotia Pilot Program to Address ADHD and ASD Wait ListsNew Nova Scotia Pilot Program to Address ADHD and ASD Wait Lists A new...
-
September 8, 2023 FOQUEST has now been included on the Newfoundland and Labrador Prescription Drug Program (NLPDP) as of Aug 30, 2023FOQUEST has now been included on the Newfoundland and Labrador Prescription Drug Program (NLPDP) as...
